【摘要】：目的探討復(fù)發(fā)難治性惡性腦膜瘤的抗血管生成治療療效。方法回顧性分析復(fù)發(fā)難治性惡性腦膜瘤使用抗血管生成藥物貝伐珠單抗治療的3例病例臨床資料。結(jié)果 3例患者使用貝伐珠單抗后MRI均可見到T2 FLAIR相水腫范圍縮小,2例患者增強(qiáng)病灶穩(wěn)定,1例患者縮小。3例患者臨床癥狀均有緩解,無疾病進(jìn)展時(shí)間分別為2.5、5、7個(gè)月。結(jié)論貝伐珠單抗使用于常規(guī)治療后復(fù)發(fā)難治性的惡性腦膜瘤大部分患者可獲得臨床癥狀緩解,影像上腫瘤控制,但控制時(shí)間有限,難達(dá)到臨床治愈。
[Abstract]:Objective to investigate the effect of anti-angiogenesis in recurrent refractory malignant meningioma. Methods the clinical data of 3 patients with refractory malignant meningioma treated with antiangiogenic drug bevacizumab were retrospectively analyzed. Results after the use of bevacizumab in 3 patients, the range of T2 FLAIR edema was reduced in MRI, the enhancement focus was stable in 2 patients, and the clinical symptoms were reduced in 1 patient. The clinical symptoms of 3 patients were relieved, and the time of no disease progression was 2. 5%, respectively. Seven months. Conclusion bevacizumab can be used in most patients with recurrent and refractory malignant meningioma after conventional therapy. The clinical symptoms can be alleviated and the tumor can be controlled on image, but the control time is limited and it is difficult to be cured clinically.
【作者單位】： 廣東三九腦科醫(yī)院腫瘤綜合治療中心;
【分類號(hào)】：R739.45

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳南寧,梁樹立,彭林,漆松濤;惡性腦膜瘤的治療及預(yù)后(附3例報(bào)告)[J];第一軍醫(yī)大學(xué)學(xué)報(bào);2000年01期

2 公茂青,王運(yùn)杰,吳杰;良惡性腦膜瘤T淋巴細(xì)胞Ag-NORs表達(dá)活性的研究[J];中華神經(jīng)外科雜志;2001年06期

3 孫金龍,于華強(qiáng),魏麟,龐琦,張慶林,鮑秀峰,孫煒;惡性腦膜瘤的臨床診斷及治療[J];山東大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2002年02期

4 胡波,常義,劉宏毅,黃慶玖,張平;惡性腦膜瘤的臨床和病理(附12例報(bào)告)[J];中國臨床神經(jīng)外科雜志;2002年01期

5 張龍,梅良奎,汪新華,宋蓮淑;惡性腦膜瘤顱外轉(zhuǎn)移一例[J];中華神經(jīng)外科雜志;2003年04期

6 王，

本文編號(hào)：2372817